Fresenius gets option rights on up to 37 first-to-market biosimilar candidates developed by WuXi Biologics, starting with copies of Roche’s Polivy and Amgen’s Tepezza. Fresenius picks the programs and keeps the economics; WuXi Biologics builds them for a per-program fee.
High-profile drugs under the legal spotlight in 2023
In the wake of the COVID-19 pandemic, the U.S. has witnessed a surge in litigation. One factor driving the uptick in the pharmaceutical sector is the rise of copycat litigation. As mass tort activity amplifies, plaintiff lawyers are treating previously filed lawsuits as templates for new claims. Examples of the trend include steadily increasing nitrosamines…

